Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome

BMC Res Notes. 2012 Apr 30:5:205. doi: 10.1186/1756-0500-5-205.

Abstract

Background: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare but severe and sometimes fatal condition associated with exposure to medications; sulfamethoxazole is among the most common causes. We sought to address the safety of acetazolamide, a chemically related compound, in patients with prior SJS/TEN and glaucoma. A retrospective case series is described of patients at the Massachusetts Eye and Ear Infirmary who underwent keratoprosthesis surgery for corneal blindness from SJS/TEN, and later required oral acetazolamide for elevated intraocular pressure.

Findings: Over the last 10 years, 17 patients with SJS/TEN received a Boston keratoprosthesis. Of these, 11 developed elevated intraocular pressure that required administration of oral acetazolamide. One of 11 developed a mild allergic reaction, but no patient experienced a recurrence of SJS/TEN or any severe adverse reaction.

Conclusion: Although an increase in the rate of recurrent SJS/TEN due to oral acetazolamide would not necessarily be apparent after treating only 11 patients, in our series, acetazolamide administration was well tolerated without serious sequela.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetazolamide / administration & dosage*
  • Administration, Oral
  • Adolescent
  • Adult
  • Boston
  • Carbonic Anhydrase Inhibitors / administration & dosage*
  • Cornea / surgery
  • Female
  • Glaucoma / prevention & control*
  • Humans
  • Intraocular Pressure / drug effects
  • Male
  • Middle Aged
  • Polymethyl Methacrylate*
  • Prostheses and Implants*
  • Retrospective Studies
  • Stevens-Johnson Syndrome / complications
  • Stevens-Johnson Syndrome / surgery
  • Titanium*

Substances

  • Carbonic Anhydrase Inhibitors
  • Polymethyl Methacrylate
  • Titanium
  • Acetazolamide